Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer

被引：0
|
作者：
Suarez-Carmona, Meggy [1 ,2 ]
Halama, Niels [1 ,2 ,3 ,4 ]
机构：
[1] German Canc Res Ctr, Dept Canc Immunol & Canc Immunotherapy, Heidelberg, Germany
[2] Helmholtz Inst Translat Oncol HI TRON, Mainz, Germany
[3] Johannes Gutenberg Univ Mainz, Univ Canc Ctr Mainz UCT Mainz, Univ Med Ctr, Mainz, Germany
[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Hematol Med Oncol & Pneumol, Mainz, Germany
来源：
TRENDS IN CANCER | 2024年 / 10卷 / 12期
关键词：
MISMATCH REPAIR-DEFICIENT; NIVOLUMAB;
D O I：
10.1016/j.trecan.2024.10.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.
引用
收藏
页码：1093 / 1094
页数：2
相关论文
共 50 条
  • [1] Neoadjuvant immunotherapy with prolgolimab in locally advanced MSI/dMMR colorectal cancer: Safety and efficacy analysis
    Zagidullina, A. A.
    Kuznetsova, O. A.
    Tryakin, A.
    Fedyanin, M.
    Aliev, V.
    Malikhova, O.
    Stroganova, A.
    Polynovskiy, A.
    Karasjov, I.
    Mamedli, Z.
    ANNALS OF ONCOLOGY, 2024, 35 : S22 - S22
  • [2] Nonoperative Management of dMMR/MSI-H Colorectal Cancer following Neoadjuvant Immunotherapy: A Narrative Review
    Xiao, Binyi
    Yu, Jiehai
    Ding, Pei-Rong
    CLINICS IN COLON AND RECTAL SURGERY, 2023, 36 (06) : 378 - 384
  • [3] Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
    Qi Zhang
    Jian Li
    Lin Shen
    Yongsheng Li
    Xicheng Wang
    Cancer Biology & Medicine, 2023, 20 (10) : 706 - 712
  • [4] Immunotherapy Promising for Metastatic MSI-H/dMMR Colorectal Cancer
    Yarden, Ronit
    ONCOLOGY-NEW YORK, 2019, 33 (05): : 179 - 179
  • [5] Opportunities and challenges of immunotherapy for dMMR/ MSI-H colorectal cancer
    Zhang, Qi
    Li, Jian
    Shen, Lin
    Li, Yongsheng
    Wang, Xicheng
    CANCER BIOLOGY & MEDICINE, 2023, 20 (10) : 706 - 712
  • [6] Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
    Qi Zhang
    Jian Li
    Lin Shen
    Yongsheng Li
    Xicheng Wang
    Cancer Biology & Medicine, 2023, (10) : 706 - 712
  • [7] Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
    Zhang, Xuan
    Wu, Tao
    Cai, Xinyi
    Dong, Jianhua
    Xia, Cuifeng
    Zhou, Yongchun
    Ding, Rong
    Yang, Renfang
    Tan, Jing
    Zhang, Lijuan
    Zhang, Ya
    Wang, Yuqin
    Dong, Chao
    Li, Yunfeng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] Pathological response following neoadjuvant immunotherapy and imaging characteristics in dMMR/MSI-H locally advanced colorectal cancer
    Deng, Zijian
    Luo, Yajun
    Chen, Xiaoli
    Pan, Tao
    Rui, Yuanyi
    Hu, Hai
    Yan, Jin
    Zhang, Ke
    Luo, Cheng
    Song, Bo
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [9] Neoadjuvant Immunotherapy Alone for Patients With Locally Advanced and Resectable Metastatic Colorectal Cancer of dMMR/MSI-H Status
    Li, Yingjie
    Tan, Luxin
    Chen, Nan
    Liu, Xinzhi
    Liang, Fei
    Yao, Yunfeng
    Zhang, Xiaoyan
    Wu, Aiwen
    DISEASES OF THE COLON & RECTUM, 2024, 67 (11) : 1413 - 1422
  • [10] Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients
    Margalit, Ofer
    Stemmer, Amos
    Chapin, William J.
    Shacham-Shmueli, Einat
    Kopetz, Scott
    Andre, Thierry
    Overman, Michael J.
    Pietrantonio, Filippo
    Boursi, Ben
    EUROPEAN JOURNAL OF CANCER, 2024, 212
12345